Michael Hunt joined ReNeuron in 2001. Between 2005 and 2014 he served as its CEO, leading the business through its early development to its current position as one of the global, clinical-stage leaders in the regenerative medicine field. He was appointed Chief Financial Officer in 2014.
He is a founding member and co-chair of the European Section of the US-based Alliance for Regenerative Medicine (ARM) and is a main board member of ARM. He also sits on the BioIndustry Association’s Cell & Gene Therapy Advisory Committee and its Finance and Tax Advisory Committee. He currently sits as a member of the Cell & Gene Therapy Catapult’s Advisory Panel.
Prior to ReNeuron, he spent six years at Biocompatibles International plc (sold to BTG plc) where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. He read economics at University College London and qualified as a chartered accountant with Ernst & Young